Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma

Cancer

Volumn 95, Issue 12, 2002, Pages 2455-2464

  Daling, Janet R ^a,b   Malone, Kathleen E ^a,b   Doody, David R ^a   Voigt, Lynda F ^a   Bernstein, Leslie ^c   Coates, Ralph J ^d   Marchbanks, Polly A ^e   Norman, Sandra A ^f   Weiss, Linda K ^g   Ursin, Giske ^c   Berlin, Jesse A ^f   Burkman, Ronald T ^h   Deapen, Dennis ^c   Folger, Suzanne G ^e   McDonald, Jill A ^e   Simon, Michael S ^g   Strom, Brian L ^f   Wingo, Phyllis A ⁱ   Spirtas, Robert ^j  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h Baystate Medical Center   (United States)

ⁱ AMERICAN CANCER SOCIETY   (United States)

^j EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

Combined hormone replacement therapy; Ductal; Histologic types of breast carcinoma; Lobular; Regimens of hormone replacement therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ESTROGEN THERAPY; ETHNIC GROUP; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZATION; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; PROGESTINS; RISK FACTORS; UNITED STATES;

EID: 0037114776     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10984     Document Type: Article

References (28)

1. Li CL, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561-2569.
2. Surveillance, Epidemiology, and End Results (SEER) Program. Public-use Data (1973-1998) Released April 2001 [Based on the August 2000 Submission]. Bethesda: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2001.
3. Newcomer LM, Newcomb PA, Daling JR, Yasui Y, Potter JD. Post-menopausal hormone use and risk of breast cancer by histologic type. Presented at the Society of Epidemiologic Research 1999 SER Meeting, Baltimore, MD June 10-12, 1999.
4. Li CL, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88:2570-2577.
5. Chen C-L, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-747.
6. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology. Results of the Iowa Women's Study. JAMA. 1999;281:2091-2097.
7. Du Toit RS, Locker AP, Ellis IO, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol. 1991;17:251-257.
8. Marchbanks PA, McDonald JA, Wilson HG, et al. The NICHD women's contraceptive and reproductive experiences study: Methods and operational results. Ann Epidemiol. 2002;12: 213-221.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
10. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998;147:718-721.
11. West SL, Strom BL. Validity of pharmacoepidemiology drug and diagnosis data. In: Strom BL, editor. Pharmacoepidemiology, 3rd Ed, chapter 39. Sussex: John Wiley & Sons, Inc., 2000:661-705.
12. O'Connor I, Shembekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: A histological and immunohistological study. J Clin Pathol. 1998;51:935-938.
13. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol. 1995;85:11-17.
14. Manjer J, Malina J, Berglund G, Bondeson L, Game JP, Janzon L. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer. 2001;92:919-922.
15. Ross RK, Paganni-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: Estrogen vs. estrogen plus progestin. J Natl Cancer Inst. 2000;92:328-332.
16. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen-and oestrogen-progestin replacement therapy. Int J Cancer. 1999;81:339-344.
17. Magnusson C, Persson I, Adami HO. More about: effect of hormone replacement therapy on breast cancer risk: Estrogen vs. estrogen plus progestin. J Natl Cancer Inst. 2000;92: 1183-1184.
18. Azzopardi JG. Classification of primary breast carcinoma. In: Azzopardi JG, Ahmed A, Millis RR, eds. Problems in Breast Pathology. Major Problems in Pathology, chapter 11, 1st ed. Eastbourne: WB Saunders, 1979:240-257.
19. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, Svan Zwieten FJ. Biology of disease. Comparative study of human and rat mammary tumorigenesis. Lab Invest. 1990; 62:244-278.
20. Russo J, Rivera R, Russo IH. Influence of age and parity on the development of the human breast. Breast Cancer Res Treat. 1992;23:211-218.
21. Gompel A, Somai S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 2000;65: 593-598.
22. Musgrove EA, Lee CSL, Sutherland R. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol. 1995;11:5032-5043.
23. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998;69:963-1060.
24. Druckmann R. Mammary effects of progestins. J Women's Cancer. 2000;2:85-92.
25. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
26. Schairer C, Lubin J, Troisi R, Strugeon SR, Brinton L, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer. JAMA. 2000;283:485-491.
27. Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997;76: 1234-1240.
28. Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73:1673-1677.